Effects of acupuncture and moxibustion in a mouse model of allergic rhinitis.
OBJECTIVE
In this study, the authors examined the effects of acupuncture and moxibustion on the expression of various inflammatory cells and mediators in the nasal mucosa of an allergic rhinitis (AR) animal model.


METHODS
Randomized controlled animal study.


METHODS
Animal laboratory in a Dongguk University.


METHODS
Twenty-eight BALB/c mice were divided into 4 groups: control, levocetirizine (Lcz), moxibustion (Mox), and acupuncture (Acu). To induce AR, mice were intraperitoneally sensitized to ovalbumin (OVA) and challenged with intranasal OVA. At 7 days following the final sensitization and every day for a further 7 days, the Lcz group was orally administered levocetirizine (50 mg/kg), the Mox group was subjected to 5 seconds of moxibustion stimulation at the juncture of the medial canthus and nostril, and the Acu group was subjected to 30 seconds of acupuncture stimuli at the same point. The authors measured the degree of positive reaction to substance P, STAT6, nuclear factor kappa B (NFκB), and iNOS via immunohistochemical staining of the nasal mucosa.


RESULTS
The degree of positive reaction to substance P, STAT6, NFκB, and iNOS was markedly decreased in the treatment groups compared to that in the control group. Notably, the above indices were most significantly decreased in the Acu group, followed by the Mox group and then the Lcz group (P = .000).


CONCLUSIONS
In an allergic rhinitis animal model, acupuncture and moxibustion are shown to exhibit an antiallergic effect and exert their effects by reducing the expression of substance P, STAT6, NFκB, and iNOS.
Department of Oriental Medicine, The Graduate School of Dongguk University, Gyeongju, Republic of Korea.
Dallim
D
Jung
Seungdeok
S
Lee
Seungug
S
Hong
D015670:Acupuncture Therapy / Q000379:methods*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D007150:Immunohistochemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D009071:Moxibustion / Q000379:methods; D009297:Nasal Mucosa / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D012221:Rhinitis, Allergic, Perennial / Q000378:metabolism / Q000628:therapy*; D050800:STAT6 Transcription Factor / Q000378:metabolism; D013373:Substance P / Q000378:metabolism; D016896:Treatment Outcome; D000097782:NF-kappaB-Inducing Kinase
D015415:Biomarkers; D052247:Nitric Oxide Synthase Type II; D017346:Protein Serine-Threonine Kinases; D050800:STAT6 Transcription Factor; D013373:Substance P; D000097782:NF-kappaB-Inducing Kinase; C494100:Stat6 protein, mouse